You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 8, 2025

Drug Price Trends for RAPIVAB


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for RAPIVAB

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
RAPIVAB 10MG/ML INJ,SOLN BioCryst Pharmaceuticals, Inc. 72769-0181-03 20X3ML 725.63 2024-01-01 - 2026-05-14 FSS
RAPIVAB 10MG/ML INJ,SOLN BioCryst Pharmaceuticals, Inc. 72769-0181-03 20X3ML 708.79 2021-05-15 - 2026-05-14 FSS
RAPIVAB 10MG/ML INJ,SOLN BioCryst Pharmaceuticals, Inc. 72769-0181-03 20X3ML 725.63 2022-01-01 - 2026-05-14 FSS
RAPIVAB 10MG/ML INJ,SOLN BioCryst Pharmaceuticals, Inc. 72769-0181-03 20X3ML 725.63 2023-01-01 - 2026-05-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

RAPIVAB Market Analysis and Financial Projection

RAPIVAB: Market Analysis and Price Projections

RAPIVAB, also known by its generic name peramivir, is an antiviral medication used to treat acute uncomplicated influenza in patients 18 years and older. As a single-dose intravenous (IV) neuraminidase inhibitor, RAPIVAB has carved out a unique position in the influenza treatment market. This article delves into the current market status, future projections, and pricing strategies for RAPIVAB.

The Influenza Treatment Landscape

Understanding RAPIVAB's Role

RAPIVAB stands out in the influenza treatment market due to its unique administration method. Unlike oral medications such as oseltamivir (Tamiflu), RAPIVAB is administered as a single IV dose, making it particularly useful for patients who have difficulty taking oral medications or those with severe symptoms.

Competitive Landscape

The influenza treatment market is competitive, with several established players. Key competitors include:

  1. Oseltamivir (Tamiflu)
  2. Zanamivir (Relenza)
  3. Baloxavir marboxil (Xofluza)

RAPIVAB's unique selling proposition lies in its single-dose IV administration, which can be advantageous in certain clinical scenarios.

Market Analysis

Current Market Position

RAPIVAB, developed by BioCryst Pharmaceuticals, has been approved for use in the United States since 2014. Its market share, while not as substantial as oral antivirals, has been steadily growing, particularly in hospital settings.

According to BioCryst's financial reports, RAPIVAB generated $13.9 million in revenue in 2024 from a U.S. government contract for the Strategic National Stockpile[5].

Market Drivers

Several factors are driving the growth of RAPIVAB in the influenza treatment market:

  1. Increasing awareness of influenza complications
  2. Growing demand for rapid-acting treatments
  3. Rise in hospitalization rates due to severe influenza cases
  4. Government stockpiling for pandemic preparedness

Market Challenges

Despite its unique advantages, RAPIVAB faces some challenges:

  1. Competition from established oral antivirals
  2. Limited use in outpatient settings due to IV administration
  3. Seasonal nature of influenza, affecting consistent demand

Future Market Projections

Growth Potential

The global influenza treatment market is expected to grow significantly in the coming years. RAPIVAB, with its unique administration method, is well-positioned to capture a portion of this growth.

Expansion Opportunities

BioCryst is exploring opportunities to expand RAPIVAB's market presence:

  1. Pediatric indications
  2. Combination therapies
  3. Use in high-risk patient populations

Potential Market Size

While specific projections for RAPIVAB are not publicly available, the overall influenza treatment market is expected to reach $1.2 billion by 2026, according to industry analysts.

Pricing Strategies

Current Pricing

The pricing of RAPIVAB varies depending on the market and procurement method. For government contracts, the pricing is negotiated based on volume and strategic importance.

Factors Influencing Pricing

Several factors influence RAPIVAB's pricing strategy:

  1. Manufacturing costs
  2. Research and development expenses
  3. Competitive landscape
  4. Government negotiations for stockpile purchases
  5. Reimbursement policies of healthcare systems

Future Pricing Projections

While exact future pricing is difficult to predict, several trends may influence RAPIVAB's pricing:

  1. Increased competition may put downward pressure on prices
  2. Expansion into new indications could justify premium pricing
  3. Government contracts may provide stable, negotiated pricing

Government Contracts and Strategic Stockpiles

U.S. Government Contracts

RAPIVAB has secured significant contracts with the U.S. government for strategic stockpiling:

In 2024, BioCryst was awarded a contract worth up to $69 million by the U.S. Department of Health and Human Services for the procurement of up to 95,625 doses of RAPIVAB over a five-year period[5].

Impact on Market Position

These government contracts provide several advantages:

  1. Stable revenue stream
  2. Enhanced market credibility
  3. Potential for increased institutional adoption

Global Market Expansion

Current Global Presence

RAPIVAB is approved in several countries, including the United States, Japan, and South Korea. Expansion into other markets represents a significant growth opportunity.

Regulatory Challenges

Expanding into new markets requires navigating complex regulatory environments. BioCryst must adapt its strategies to meet diverse regulatory requirements across different regions.

Potential New Markets

Emerging economies with growing healthcare infrastructure represent potential new markets for RAPIVAB. Countries with high influenza burden and improving healthcare systems are particularly attractive targets.

Research and Development Pipeline

Ongoing Studies

BioCryst continues to invest in research to expand RAPIVAB's indications and improve its efficacy:

  1. Pediatric studies
  2. Combination therapy trials
  3. Studies in immunocompromised patients

Future Innovations

Potential future developments for RAPIVAB include:

  1. Extended-release formulations
  2. Combination products with other antivirals
  3. Novel delivery methods to improve outpatient use

Manufacturing and Supply Chain

Current Manufacturing Capacity

BioCryst has established manufacturing partnerships to ensure a stable supply of RAPIVAB. The company's ability to meet large government orders demonstrates robust manufacturing capabilities.

Supply Chain Considerations

Maintaining a reliable supply chain is crucial for RAPIVAB's success:

  1. Raw material sourcing
  2. Quality control measures
  3. Distribution network efficiency
  4. Inventory management for seasonal demand

Reimbursement Landscape

Current Reimbursement Status

RAPIVAB's reimbursement status varies by country and healthcare system. In the U.S., it is covered by many insurance plans, particularly for hospitalized patients.

Future Reimbursement Trends

Changes in healthcare policies and reimbursement models could impact RAPIVAB's market access:

  1. Value-based pricing models
  2. Outcomes-based reimbursement
  3. Changes in government healthcare programs

Marketing and Promotion Strategies

Target Audience

RAPIVAB's marketing efforts primarily focus on:

  1. Hospital administrators
  2. Emergency department physicians
  3. Infectious disease specialists
  4. Government health agencies

Key Marketing Messages

BioCryst's marketing strategy emphasizes RAPIVAB's unique benefits:

  1. Single-dose administration
  2. Rapid onset of action
  3. Efficacy in severe influenza cases
  4. Utility in patients unable to take oral medications

Competitive Advantages and Challenges

Strengths

  1. Unique IV administration
  2. Rapid onset of action
  3. Strong government contracts
  4. Established safety profile

Challenges

  1. Limited outpatient use
  2. Seasonal demand fluctuations
  3. Competition from oral antivirals
  4. Need for healthcare professional administration

Future Outlook and Market Trends

Emerging Technologies

Advancements in antiviral technologies could impact RAPIVAB's market position:

  1. Novel mechanisms of action
  2. Universal influenza vaccines
  3. Improved diagnostic tools

Changing Treatment Paradigms

Shifts in influenza treatment approaches may influence RAPIVAB's future:

  1. Increased focus on early intervention
  2. Combination antiviral therapies
  3. Personalized treatment based on viral strain and patient factors

Key Takeaways

  1. RAPIVAB holds a unique position in the influenza treatment market as a single-dose IV antiviral.
  2. Government contracts provide a stable revenue stream and enhance market credibility.
  3. Future growth opportunities lie in expanding indications and global market presence.
  4. Pricing strategies must balance competitiveness with the need to recoup R&D investments.
  5. Ongoing research and development efforts aim to strengthen RAPIVAB's market position.
  6. Supply chain management and manufacturing capacity are crucial for meeting demand.
  7. Reimbursement policies and healthcare system changes will impact RAPIVAB's market access.
  8. Marketing efforts focus on highlighting RAPIVAB's unique benefits to healthcare professionals.
  9. Emerging technologies and changing treatment paradigms may present both opportunities and challenges.
  10. RAPIVAB's future success will depend on adapting to market trends and leveraging its competitive advantages.

FAQs

  1. Q: How does RAPIVAB differ from other influenza treatments? A: RAPIVAB is unique in that it's administered as a single intravenous dose, unlike oral medications that require multiple doses over several days.

  2. Q: Is RAPIVAB effective against all strains of influenza? A: RAPIVAB is effective against both influenza A and B strains, but its efficacy can vary depending on the specific viral strain and patient factors.

  3. Q: Can RAPIVAB be used in pediatric patients? A: Currently, RAPIVAB is approved for use in patients 18 years and older. However, studies are ongoing to evaluate its safety and efficacy in pediatric populations.

  4. Q: How does government stockpiling affect RAPIVAB's market position? A: Government contracts for stockpiling provide a stable revenue stream and enhance RAPIVAB's credibility in the market, potentially leading to increased adoption in healthcare settings.

  5. Q: What are the main challenges facing RAPIVAB in the competitive influenza treatment market? A: Key challenges include competition from established oral antivirals, limited outpatient use due to IV administration, and the seasonal nature of influenza affecting consistent demand.

Sources cited: [2] https://www.globenewswire.com/news-release/2024/11/04/2973912/29446/en/BioCryst-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Business-Update.html [4] https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS00212 [5] https://www.stocktitan.net/news/BCRX/u-s-government-awards-bio-cryst-69-million-rapivab-r-peramivir-zgcozaxpqfd6.html

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.